Stifel analysts maintained a Buy rating and a $72.00 price target for LivaNova (NASDAQ:LIVN), following news from Swedish ...
Beta Bionics is targeting a valuation of up to $695 million in an upsized initial public offering, the insulin delivery device maker said on Tuesday. The company will aim to raise up to $170 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback